Ratings BioNTech SE Xetra

Equities

22UA

US09075V1026

Real-time Estimate Tradegate Other stock markets 03:09:12 2024-05-21 EDT			5-day change	1st Jan Change
84.2 ^EUR	+0.72%		-2.68%	-12.02%

05-17	Sector Update: Health Care Stocks Mixed Late Afternoon	MT
05-17	Sector Update: Health Care Stocks Softer Friday Afternoon	MT

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

Thanks to a sound financial situation, the firm has significant leeway for investment.
The company appears to be poorly valued given its net asset value.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Over the past four months, analysts' average price target has been revised downwards significantly.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
Over the past twelve months, analysts' opinions have been revised negatively.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
BIONTECH SE	-12.02%	22.31B	-
VERTEX PHARMACEUTICALS INCORPORATED	+9.58%	115B	B+
REGENERON PHARMACEUTICALS, INC.	+12.41%	107B	B+
ARGENX SE	-3.38%	21.6B	B
GENMAB A/S	-5.29%	19.19B	A-
BEIGENE, LTD.	-3.35%	18.23B	B
WUXI APPTEC CO., LTD.	-38.57%	17.62B	A-
NEUROCRINE BIOSCIENCES, INC.	+7.51%	14.26B	C+
SAREPTA THERAPEUTICS, INC.	+35.67%	12.37B	C+
LEGEND BIOTECH CORPORATION	-24.50%	8.28B	D

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes